394 related articles for article (PubMed ID: 16690720)
1. Mu-delta opioid receptor functional interaction: Insight using receptor-G protein fusions.
Snook LA; Milligan G; Kieffer BL; Massotte D
J Pharmacol Exp Ther; 2006 Aug; 318(2):683-90. PubMed ID: 16690720
[TBL] [Abstract][Full Text] [Related]
2. Comparison of [Dmt1]DALDA and DAMGO in binding and G protein activation at mu, delta, and kappa opioid receptors.
Zhao GM; Qian X; Schiller PW; Szeto HH
J Pharmacol Exp Ther; 2003 Dec; 307(3):947-54. PubMed ID: 14534366
[TBL] [Abstract][Full Text] [Related]
3. Modulation by mu-opioid agonists of guanosine-5'-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells.
Traynor JR; Nahorski SR
Mol Pharmacol; 1995 Apr; 47(4):848-54. PubMed ID: 7723747
[TBL] [Abstract][Full Text] [Related]
4. Stimulation of guanosine-5'-o-(3-[35S]thio)triphosphate binding in digitonin-permeabilized C6 rat glioma cells: evidence for an organized association of mu-opioid receptors and G protein.
Alt A; McFadyen IJ; Fan CD; Woods JH; Traynor JR
J Pharmacol Exp Ther; 2001 Jul; 298(1):116-21. PubMed ID: 11408532
[TBL] [Abstract][Full Text] [Related]
5. Characterization of opioid agonist efficacy in a C6 glioma cell line expressing the mu opioid receptor.
Emmerson PJ; Clark MJ; Mansour A; Akil H; Woods JH; Medzihradsky F
J Pharmacol Exp Ther; 1996 Sep; 278(3):1121-7. PubMed ID: 8819494
[TBL] [Abstract][Full Text] [Related]
6. Hetero-oligomers of alpha2A-adrenergic and mu-opioid receptors do not lead to transactivation of G-proteins or altered endocytosis profiles.
Zhang YQ; Limbird LE
Biochem Soc Trans; 2004 Nov; 32(Pt 5):856-60. PubMed ID: 15494033
[TBL] [Abstract][Full Text] [Related]
7. Differential coupling of mu-, delta-, and kappa-opioid receptors to G alpha16-mediated stimulation of phospholipase C.
Lee JW; Joshi S; Chan JS; Wong YH
J Neurochem; 1998 May; 70(5):2203-11. PubMed ID: 9572309
[TBL] [Abstract][Full Text] [Related]
8. Modulation by neuropeptide FF of the interaction of mu-opioid (MOP) receptor with G-proteins.
Kersanté F; Moulédous L; Zajac JM; Mollereau C
Neurochem Int; 2010; 56(6-7):768-73. PubMed ID: 20211672
[TBL] [Abstract][Full Text] [Related]
9. Effect of ethanol self-administration on mu- and delta-opioid receptor-mediated G-protein activity.
Sim-Selley LJ; Sharpe AL; Vogt LJ; Brunk LK; Selley DE; Samson HH
Alcohol Clin Exp Res; 2002 May; 26(5):688-94. PubMed ID: 12045478
[TBL] [Abstract][Full Text] [Related]
10. Co-expression of mu and delta opioid receptors as receptor-G protein fusions enhances both mu and delta signalling via distinct mechanisms.
Snook LA; Milligan G; Kieffer BL; Massotte D
J Neurochem; 2008 May; 105(3):865-73. PubMed ID: 18182056
[TBL] [Abstract][Full Text] [Related]
11. Chronic antidepressant treatment causes a selective reduction of mu-opioid receptor binding and functional coupling to G Proteins in the amygdala of fawn-hooded rats.
Chen F; Lawrence AJ
J Pharmacol Exp Ther; 2004 Sep; 310(3):1020-6. PubMed ID: 15121763
[TBL] [Abstract][Full Text] [Related]
12. Chronic agonist treatment converts antagonists into inverse agonists at delta-opioid receptors.
Liu JG; Prather PL
J Pharmacol Exp Ther; 2002 Sep; 302(3):1070-9. PubMed ID: 12183665
[TBL] [Abstract][Full Text] [Related]
13. Opioid peptide receptor studies. 17. Attenuation of chronic morphine effects after antisense oligodeoxynucleotide knock-down of RGS9 protein in cells expressing the cloned Mu opioid receptor.
Xu H; Wang X; Wang J; Rothman RB
Synapse; 2004 Jun; 52(3):209-17. PubMed ID: 15065220
[TBL] [Abstract][Full Text] [Related]
14. Novel diastereomeric opioid tetrapeptides exhibit differing pharmacological activity profiles.
Ioja E; Tourwé D; Kertész I; Tóth G; Borsodi A; Benyhe S
Brain Res Bull; 2007 Sep; 74(1-3):119-29. PubMed ID: 17683797
[TBL] [Abstract][Full Text] [Related]
15. [Effects of newly isolated opioid peptides on G-protein activation: usefulness of [35S] GTP gamma S binding study and its practical application].
Narita M
Nihon Shinkei Seishin Yakurigaku Zasshi; 1998 Aug; 18(4):107-16. PubMed ID: 9866825
[TBL] [Abstract][Full Text] [Related]
16. In vivo injection of antisense oligodeoxynucleotides to G alpha subunits and supraspinal analgesia evoked by mu and delta opioid agonists.
Sánchez-Blázquez P; García-España A; Garzón J
J Pharmacol Exp Ther; 1995 Dec; 275(3):1590-6. PubMed ID: 8531133
[TBL] [Abstract][Full Text] [Related]
17. Supersensitivity to mu-opioid receptor-mediated inhibition of the adenylyl cyclase pathway involves pertussis toxin-resistant Galpha protein subunits.
Mostany R; Díaz A; Valdizán EM; Rodríguez-Muñoz M; Garzón J; Hurlé MA
Neuropharmacology; 2008 May; 54(6):989-97. PubMed ID: 18384820
[TBL] [Abstract][Full Text] [Related]
18. Signal transduction correlates of mu opioid agonist intrinsic efficacy: receptor-stimulated [35S]GTP gamma S binding in mMOR-CHO cells and rat thalamus.
Selley DE; Liu Q; Childers SR
J Pharmacol Exp Ther; 1998 May; 285(2):496-505. PubMed ID: 9580589
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the binding of [3H][Dmt1]H-Dmt-D-Arg-Phe-Lys-NH2, a highly potent opioid peptide.
Neilan CL; Janvey AJ; Bolan E; Berezowska I; Nguyen TM; Schiller PW; Pasternak GW
J Pharmacol Exp Ther; 2003 Aug; 306(2):430-6. PubMed ID: 12663687
[TBL] [Abstract][Full Text] [Related]
20. Endogenous regulator of g protein signaling proteins reduce {mu}-opioid receptor desensitization and down-regulation and adenylyl cyclase tolerance in C6 cells.
Clark MJ; Traynor JR
J Pharmacol Exp Ther; 2005 Feb; 312(2):809-15. PubMed ID: 15383633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
